Current BSR guidelines

2014

BSR and BHPR guidelines for the management of adults with ANCA-associated vasculitis
(To be reviewed in 2017)
-- Executive summary
-- Full guidelines

2013

BSR and BHPR guidelines for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis
(To be reviewed in 2016)
-- Executive summary
-- Full guidelines
BSR and BHPR guidelines for the treatment of psoriatic arthritis with biologics
(To be reviewed in 2016)
-- Executive summary
-- Full guidelines
-- Audit tool

2011
BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis
-- Executive summary
-- Full guidelines

2010
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
(under revision)
-- Executive summary
-- Full guidelines
BSR and BHPR guidelines for the management of giant cell arteritis
(under revision)
-- Executive summary
-- Full guidelines
BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy
(under revision)
-- Executive summary
-- Full guidelines

2009
BSR and BHPR guidelines for the management of polymyalgia rheumatica
(under revision)
-- Executive summary
-- Full guidelines

2008
BSR and BHPR guidelines for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists
(under revision)
-- Executive summary
-- Full guidelines

2007
BSR and BHPR guidelines for the management of gout
(under revision)
-- Executive summary
-- Full guidelines

  2006
BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults
-- Executive summary
-- Full guidelines
-- Revision statement

New guidelines in development

-- Tocilizumab use in rheumatoid arthritis

-- Systematic lupus erythematosus management

-- Scleroderma management

-- Prescribing in pregnancy for rheumatology

-- Ankylosing spondylitis and biologics